TLC-ART 101 (ACTU 2001) 人类研究中的第一名
首次在下一代长效注射联合抗逆转录病毒治疗平台进行人体临床试验
研究概览
详细说明
本研究是一项针对长效、可注射联合抗逆转录病毒治疗平台的前瞻性、开放标签、单中心、首次人体研究,采用药理学指导的剂量递增、递减和研究持续时间适应性设计. 该研究有两个主要目标,如下所示:
- 表征单剂量 TLC-ART 101 药物(洛匹那韦、利托那韦和替诺福韦)的血浆浓度-时间过程和药代动力学 (PK),该药物通过药物组合纳米颗粒皮下注射给药。
- 表征单次皮下注射 TLC-ART 101 的安全性和耐受性。
有 4 个探索性的机制目标(以及相关的终点)如下:
- 表征药物在人外周血单核细胞 (PBMC) 中的药代动力学
- 表征 PBMC 中细胞内 TFV-二磷酸(TFV 的活性部分)的浓度
- 探讨单次给药后 3 种药物的药代动力学参数是否因性别而异
- 比较淋巴组织单核细胞与 TLC-ART 101 中药物的 PBMC 浓度。
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Washington
-
Seattle、Washington、美国、98104
- UW Positve Research, Harborview Medical Center
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
纳入标准:
- BMI 在 18.5 至 29.9 kg/m2 之间的健康人
- 非吸烟者或前吸烟者(定义为不吸烟或不吸电子烟或不使用戒烟产品超过 1 年)
- 任何性别的人如果符合所有其他入学标准,都有资格参加。
- 经研究人员评估为感染 HIV 的风险较低,并承诺在完成研究之前保持与 HIV 暴露的低风险一致的行为。
- 愿意并能够给予知情同意。
- 如果参与可能导致怀孕的性活动,具有生殖潜力的个体必须同意在整个研究过程中使用特定形式的避孕措施。 在整个研究过程中必须至少使用以下两项:
- 避孕套(男用或女用)
- 隔膜或宫颈帽
- 铜基宫内节育器
- 男性伴侣输精管切除术
注意:部分参与者将在 UW 医疗中心住院 72 小时。
注意:选定的参与者将接受腹股沟淋巴结活检。
排除标准:
请注意以下标准指的是筛选访问的值
- 阳性 HIV-1 第四代抗原/抗体测试
- 乙肝表面抗原检测阳性
- 活动性 HCV 感染 注意:HCV 抗体呈阳性的参与者的 HCV RNA 必须呈阴性
- 研究者认为重要的任何慢性疾病(例如哮喘、严重过敏、高血压、心脏病、糖尿病、高脂血症)
- 在进入访问前 30 天内服用任何慢性口服或全身处方药(包括留置激素植入物或释放激素的宫内节育器)
- 服用任何无法安全停止的慢性口服或全身性非处方药(非处方药,OTC)
- CBC、肌酐、AST、ALT、碱性磷酸酶、总胆红素的任何临床显着异常值
- PT/INR、PTT高于正常上限
- U/A 伴有任何有临床意义的异常
- 每次医生审查时对 ECG 的任何具有临床意义的发现
- 如果参与者同意在进入研究前 14 天和研究期间停止使用大麻,则任何非法药物(大麻除外)的尿液毒理学筛查呈阳性,并且认为这一承诺是可信的调查员)
- BP > 140 收缩压或 > 90 舒张压 mmHg
- 已知对 LPV、RTV、TFV 或 TLC-ART 101 中的任何一种脂质过敏/敏感或任何超敏反应(包括对 COVID-19 mRNA 疫苗的过敏反应)
- 现场调查员认为会干扰对研究要求的依从性的药物或酒精使用或依赖或精神疾病
- 进入研究前 90 天内需要全身治疗、抗生素和/或住院治疗的急性或严重疾病
- 腹部中央的疤痕或纹身会干扰皮下注射的给药或研究药物计划给药位置的评估(脐部 1 英寸以内)
- 过去一年内梅毒、淋病或衣原体感染的诊断
- 怀孕、打算怀孕或正在哺乳的人
将接受淋巴结活检的参与者的其他排除标准
- 对利多卡因或任何相关的“卡因”药物过敏
- 两个腹股沟区域的慢性疤痕或纹身可能会干扰淋巴结活检的性能或增加美容效果不佳的可能性
- 焦虑或任何其他极有可能干扰局部麻醉下淋巴结活检成功进行的情况
- 任何会增加出血可能性的凝血病或病症
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:TLC-ART 101 初始剂量
所有手臂都将接受洛匹那韦、利托那韦和替诺福韦 (TLC-ART 101) 的纳米颗粒悬浮液。 兵种也称为队列。 参与者接受的剂量会有所不同,具体取决于研究结果和他们参加研究的时间。 给予 4 名参与者的初始剂量将包含: 洛匹那韦 15.6 毫克、利托那韦 4.2 毫克和替诺福韦 9.15 毫克在 1.5 毫升的制剂中 如果初始剂量合适,将在第 1 组中再招募 8 名参与者,总研究规模为 12 名参与者。 |
TLC-ART 101 包含洛匹那韦、利托那韦和替诺福韦的复合纳米颗粒悬浮液
|
|
实验性的:TLC-ART 101 剂量 2A
在第 1 组的剂量产生药代动力学 (PK) 不足的情况下,第 2A 组的剂量将增加 2 倍并给予 4 名参与者。 如果第 2A 组显示出理想的 PK 参数,则另外 8 名参与者将被纳入该组,总研究规模为 16 名参与者。 |
TLC-ART 101 包含洛匹那韦、利托那韦和替诺福韦的复合纳米颗粒悬浮液
|
|
实验性的:TLC-ART 101 剂量 2B
在第 1 组的剂量产生过量药物水平的情况下,剂量将减少最多 2-5 倍(2-5 倍递减剂量)并给予 4 名参与者。 如果第 2B 组显示出理想的 PK 参数,则另外 8 名参与者将被纳入该组,总研究规模为 16 名参与者。 |
TLC-ART 101 包含洛匹那韦、利托那韦和替诺福韦的复合纳米颗粒悬浮液
|
|
实验性的:TLC-ART 101 剂量 3A
在第 2A 组的剂量产生的药物水平不足的情况下,剂量可能会比第 2A 组的剂量进一步增加 2 倍(总剂量增加 4 倍),并给予另外 4 名参与者。 如果第 3A 组显示出理想的 PK 参数,另外 4 名参与者将被纳入该组,总研究规模为 16 名参与者 |
TLC-ART 101 包含洛匹那韦、利托那韦和替诺福韦的复合纳米颗粒悬浮液
|
|
实验性的:TLC-ART 101 剂量 3B
在 Arm 2B 中的剂量产生过量药物水平的情况下,剂量可能会进一步减少至 Arm 2B 剂量的 2-5 倍(减少 4-10 倍剂量)并给予 4 名参与者。 如果第 3B 组显示出理想的 PK 参数,另外 4 名参与者将被纳入该组,总研究规模为 16 名参与者 |
TLC-ART 101 包含洛匹那韦、利托那韦和替诺福韦的复合纳米颗粒悬浮液
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Co-primary Pharmacokinetic Outcome: Peak TLC-101 Drug Substance Concentrations (Cmax) in Plasma
大体时间:Duration of follow-up in days for this study (57 days in Cohort 1 and 64 days in Cohorts 2A/2B)
|
The maximum drug substance plasma concentrations of lopinavir, ritonavir, and tenofovir obtained following a single administration.
Sampling for drug concentrations was performed at 15-, 30-, and 45-minutes post-dosing; at 1, 3, 5, 8, and 24 hours; and after 2, 3, 7, 10, 14, 21, 28, 35, 49, and 57 days in Cohort 1. Cohort 2A/2B members had an additional sample drawn at 64 days.
|
Duration of follow-up in days for this study (57 days in Cohort 1 and 64 days in Cohorts 2A/2B)
|
|
Co-primary Pharmacokinetic Outcome: Time to Maximum TLC-101 Concentration (Tmax) of Drug Substances in Plasma
大体时间:Duration of follow-up in days for this study (57 days in Cohort 1 and 64 days in Cohorts 2A/2B)
|
Time (hours) to reach the maximum concentrations of lopinavir, ritonavir, and tenofovir after a single administration of TLC-ART-101.
Sampling for drug concentrations was performed at 15-, 30-, and 45-minutes post-dosing; at 1, 3, 5, 8, and 24 hours; and after 2, 3, 7, 10, 14, 21, 28, 35, 49, and 57 days in Cohort 1. Cohort 2A/2B members had an additional sample drawn at 64 days.
|
Duration of follow-up in days for this study (57 days in Cohort 1 and 64 days in Cohorts 2A/2B)
|
|
Co-primary Pharmacokinetic Outcome: Total TLC-101 Drug Substance Exposure (Area Under the Curve or AUC) in Plasma
大体时间:Duration of follow-up in days for this study (57 days in Cohort 1 and 64 days in Cohorts 2A/2B)
|
Area under the curve of plasma concentrations of lopinavir, ritonavir, and tenofovir over the study timecourse after a single administration.
Sampling for drug concentrations was performed at 15-, 30-, and 45-minutes post-dosing; at 1, 3, 5, 8, and 24 hours; and after 2, 3, 7, 10, 14, 21, 28, 35, 49, and 57 days in Cohort 1. Cohort 2A/2B members had an additional sample drawn at 64 days.
|
Duration of follow-up in days for this study (57 days in Cohort 1 and 64 days in Cohorts 2A/2B)
|
|
Co-primary Pharmacokinetic Outcome: Estimated Half-life (T 1/2) of TLC-101 Drug Substance Concentrations in Plasma
大体时间:Duration of follow-up in days for this study (57 days in Cohort 1 and 64 days in Cohorts 2A/2B)
|
The apparent terminal half-life of drug substance plasma concentrations of lopinavir, ritonavir, and tenofovir after a single administration.
Sampling for drug concentrations was performed at 15-, 30-, and 45-minutes post-dosing; at 1, 3, 5, 8, and 24 hours; and after 2, 3, 7, 10, 14, 21, 28, 35, 49, and 57 days in Cohort 1. Cohort 2A/2B members had an additional sample drawn at 64 days.
The apparent terminal half-life T1/2,z was computed by regression on at least 3 detectable points if Tlast was at 57 or 64 days (end of study) or 2 detected and the first undetectable if Tlast < 57 or 64 days; detectable timepoints following undetectable plasma levels were excluded from the T1/2 estimation.
|
Duration of follow-up in days for this study (57 days in Cohort 1 and 64 days in Cohorts 2A/2B)
|
|
Primary Safety Outcome
大体时间:Duration of follow-up in days for this study (57 days in Cohort 1 and 64 days in Cohorts 2A/2B)
|
Treatment emergent adverse events related to TLC-ART 101 as graded by the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (Corrected Version 2.1 - July 2017).
Only related injection site reactions (ISRs) or other related systemic events are reported here.
Comprehensive adverse events, related and unrelated, are reported in the Adverse Event section.
|
Duration of follow-up in days for this study (57 days in Cohort 1 and 64 days in Cohorts 2A/2B)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
次要药代动力学结果:外周血单核细胞中 TLC-101 药物浓度与血浆水平的比较
大体时间:本研究的后续天数(预计每位参与者 57 天)
|
从与血浆分析相同的血样中表征人外周血单核细胞中三种药物的浓度
|
本研究的后续天数(预计每位参与者 57 天)
|
|
替诺福韦活性药物部分的次要结果
大体时间:57 天的研究随访
|
表征外周血单核细胞中细胞内替诺福韦二磷酸盐(TFV 的活性部分)的浓度
|
57 天的研究随访
|
|
淋巴组织中的 TLC-101 浓度
大体时间:57 天的研究随访
|
比较 TLC-ART 101 中药物物质的淋巴组织单核细胞与外周血单核细胞浓度
|
57 天的研究随访
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Pharmacokinetic Outcome: Estimated Duration of TLC-101 Drug Substance Detection in Peripheral Blood Mononuclear Cells (PBMCs)
大体时间:Sampling for drug concentrations was performed at 15-, 30-, and 45-minutes post-dosing; at 1, 3, 5, 8, and 24 hours; and after 2, 3, 7, 10, 14, 21, 28, 35, 49, and 57 days. Cohort 2A/2B had an additional sample at 64 days.
|
Concentrations of the three drug substances in human peripheral blood mononuclear cells from the same blood samples as plasma analyses Duration of drug detection in PBMCs includes the T(ALLQ), or the time in days for which drug concentrations remained persistently above the lower limit of quantification (LLQ), with detectable levels that occurred following LLQ or undetectable values censored; and Tlast, or the time in days until the last quantifiable (≥LLQ) time point regardless of intermediate undetectable/unquantifiable values. For T(ALLQ), no censoring was applied until 24hrs after administration as the drug was absorbed from the injection site. Concentrations of drugs within PBMCs often showed 2 curves, and sometimes with undetectable values between, hence presentation of TALLQ and Tlast to fully characterize the drug timecourse. TALLQ represents the more traditional clinical PK analysis wherein all values after the first LLQ are censored, and Tlast includes all timepoints. |
Sampling for drug concentrations was performed at 15-, 30-, and 45-minutes post-dosing; at 1, 3, 5, 8, and 24 hours; and after 2, 3, 7, 10, 14, 21, 28, 35, 49, and 57 days. Cohort 2A/2B had an additional sample at 64 days.
|
|
Pharmacokinetic Outcome: AUC (Area Under the Curve) of TLC-ART 101 Drug Substances in Peripheral Blood Mononuclear Cells (PBMCs)
大体时间:Sampling for drug concentrations was performed at 15-, 30-, and 45-minutes post-dosing; at 1, 3, 5, 8, and 24 hours; and after 2, 3, 7, 10, 14, 21, 28, 35, 49, and 57 days. Cohort 2A/2B had an additional sample at 64 days.
|
Total exposure of the three drug substances in human peripheral blood mononuclear cells is measured from the same blood samples as plasma analyses. Total exposure to TLC-ART 101 drug components in PBMCs is represented by the area under the curve (AUC). The AUC is presented from Time 0 through the T(ALLQ), representing total exposure throughout the time point (Endpoint #6) through which the drug has always remained above the lower limit of quantification (LLQ). |
Sampling for drug concentrations was performed at 15-, 30-, and 45-minutes post-dosing; at 1, 3, 5, 8, and 24 hours; and after 2, 3, 7, 10, 14, 21, 28, 35, 49, and 57 days. Cohort 2A/2B had an additional sample at 64 days.
|
|
Pharmacokinetic Outcome: Duration of Intracellular Tenofovir Active Drug Moiety Detection
大体时间:Sampling for drug concentrations was performed at 15-, 30-, and 45-minutes post-dosing; at 1, 3, 5, 8, and 24 hours; and after 2, 3, 7, 10, 14, 21, 28, 35, 49, and 57 days. Cohort 2A/2B had an additional sample at 64 days.
|
Duration of detection of intracellular tenofovir-diphosphate (the active moiety of TFV, or TFV-DP) in peripheral blood mononuclear cells. Duration of TFV-DP in PBMCs includes the T(ALLQ), or the time in days for which drug concentrations remained persistently above the lower limit of quantification (LLQ), with detectable levels that occurred following LLQ or undetectable values censored; and Tlast, or the time in days until the last quantifiable (≥LLQ) time point regardless of intermediate undetectable/unquantifiable values. For T(ALLQ), no censoring was applied until 24hrs after administration as the drug was absorbed from the injection site. Concentrations of drugs within PBMCs often showed 2 curves, and sometimes with undetectable values between, hence presentation of TALLQ and Tlast to fully characterize the drug timecourse. TALLQ represents the more traditional clinical PK analysis wherein all values after the first LLQ are censored, and Tlast includes all timepoints. |
Sampling for drug concentrations was performed at 15-, 30-, and 45-minutes post-dosing; at 1, 3, 5, 8, and 24 hours; and after 2, 3, 7, 10, 14, 21, 28, 35, 49, and 57 days. Cohort 2A/2B had an additional sample at 64 days.
|
|
Pharmacokinetic Outcome: AUC (Area Under the Curve) of the Intracellular Tenofovir Active Drug Moiety in Peripheral Blood Mononuclear Cells (PBMCs)
大体时间:Duration of follow-up in days for this study (57 days in Cohort 1 and 64 days in Cohorts 2A/2B)
|
Total exposure to tenofovir diphosphate (TFV-DP) in PBMCs is represented by the area under the curve (AUC).
The AUC is presented from Time 0 through the T(ALLQ), representing total exposure throughout the time point (Endpoint #8) through which TFV-DP has always remained above the lower limit of quantification (LLQ).
|
Duration of follow-up in days for this study (57 days in Cohort 1 and 64 days in Cohorts 2A/2B)
|
|
TLC-101 Concentrations in Lymphoid Tissues
大体时间:24hrs (Day 1) after TLC-ART 101 administration
|
Concentration of lymphoid tissue mononuclear cell (LMNC) drug substances in TLC-ART 101 by measuring concentrations of lopinavir, ritonavir, and tenofovir in lymph node mononuclear cells retrieved from inguinal lymph node excision at 24 hours after receipt of TLC-ART 101.
|
24hrs (Day 1) after TLC-ART 101 administration
|
|
Ratio of TLC-ART 101 Drugs in Lymph Node Mononuclear Cells (LNMC) to Peripheral Blood Mononuclear Cells (PBMC)
大体时间:24hrs (Day 1) after TLC-ART 101 administration
|
This is the ratio of the LNMC to PBMC concentration at 24hrs after TLC-ART 101 administration within the same 2 individuals
|
24hrs (Day 1) after TLC-ART 101 administration
|
合作者和调查者
调查人员
- 首席研究员:Rachel A Bender Ignacio, MD MPH、University of Washington
出版物和有用的链接
一般刊物
- Kraft JC, McConnachie LA, Koehn J, Kinman L, Collins C, Shen DD, Collier AC, Ho RJ. Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma. AIDS. 2017 Mar 27;31(6):765-770. doi: 10.1097/QAD.0000000000001405.
- Freeling JP, Koehn J, Shu C, Sun J, Ho RJ. Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates. AIDS Res Hum Retroviruses. 2015 Jan;31(1):107-14. doi: 10.1089/aid.2014.0210.
- McConnachie LA, Kinman LM, Koehn J, Kraft JC, Lane S, Lee W, Collier AC, Ho RJY. Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection. J Pharm Sci. 2018 Jul;107(7):1787-1790. doi: 10.1016/j.xphs.2018.03.005. Epub 2018 Mar 13.
- Kraft JC, Treuting PM, Ho RJY. Indocyanine green nanoparticles undergo selective lymphatic uptake, distribution and retention and enable detailed mapping of lymph vessels, nodes and abnormalities. J Drug Target. 2018 Jun-Jul;26(5-6):494-504. doi: 10.1080/1061186X.2018.1433681. Epub 2018 Feb 12.
- Perazzolo S, Shireman LM, McConnachie LA, Koehn J, Kinman L, Lee W, Lane S, Collier AC, Shen DD, Ho RJY. Integration of Computational and Experimental Approaches to Elucidate Mechanisms of First-Pass Lymphatic Drug Sequestration and Long-Acting Pharmacokinetics of the Injectable Triple-HIV Drug Combination TLC-ART 101. J Pharm Sci. 2020 May;109(5):1789-1801. doi: 10.1016/j.xphs.2020.01.016. Epub 2020 Jan 29.
- Perazzolo S, Shireman LM, Shen DD, Ho RJY. Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 1: Model for the Free-Drug Mixture. J Pharm Sci. 2022 Feb;111(2):529-541. doi: 10.1016/j.xphs.2021.10.007. Epub 2021 Oct 19.
- Perazzolo S, Shen DD, Ho RJY. Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 2: Model for the Drug-combination Nanoparticles. J Pharm Sci. 2022 Mar;111(3):825-837. doi: 10.1016/j.xphs.2021.10.009. Epub 2021 Oct 19.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- STUDY00007490
- U01AI148055 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
IPD 共享时间框架
IPD 共享支持信息类型
- 研究方案
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.